Imidazoquinolines: Recent Developments in Anticancer Activity

Area of Science:

• Oncology
• Immunology
• Medicinal Chemistry

Background:

• Cancer remains a significant global health challenge despite advances in drug discovery.
• Small-molecule agonists of toll-like receptor 7 and 8 (TLR7/8) are emerging as promising anticancer agents.
• Imidazoquinolines and dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors represent key therapeutic candidates.

Purpose of the Study:

• To review the synthesis, structure-activity relationships (SAR), and biological activities of clinically studied imidazoquinolines.
• To explore novel preclinical imidazoquinolines with potential anticancer applications.
• To consolidate current knowledge on TLR7/8 agonists in cancer therapy.

Main Methods:

• Literature review of preclinical and clinical studies on imidazoquinolines.
• Analysis of synthesis pathways and SAR data for anticancer efficacy.
• Evaluation of biological activities, including antitumoral effects.

Main Results:

• Imidazoquinolines demonstrate profound antitumoral activity through TLR7/8 agonism.
• Clinically relevant compounds like Imiquimod and Resiquimod showcase therapeutic potential.
• Emerging preclinical imidazoquinolines offer new avenues for cancer treatment development.

Conclusions:

• TLR7/8 agonists, particularly imidazoquinolines, are vital in advancing cancer drug discovery.
• Understanding SAR is crucial for optimizing the design of novel anticancer agents.
• Continued research into imidazoquinolines holds promise for improved cancer patient outcomes.